TNET

ANALYST NOTE: TNET (TriNet Group, Inc.) Date: 2026-06-20 Current Price: $45.29

1. Structural Readiness

State: Context-Only Conservative Entry: — (Awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: — (Not actionable on forming structure alone) Breakout Level: — (Not yet established) Current Price: $45.29 Extension: — ATR Current: 4.6% (High)

Structural Assessment:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Macro Thesis: None named at this date.

This is a tactical, setup-led name. There is no named secular macro thesis driving the immediate conviction. The investment case rests entirely on the quality of the structural setup (the forming coil) and the underlying business fundamentals as reported by management. We are not assigning a macro narrative (e.g., "AI-driven HR revolution" or "SMB recovery") as a primary driver; rather, we are judging the name on its ability to execute its stated guidance and the technical readiness of the price structure.

3. The Business

Company Overview: TriNet Group, Inc. is a leading provider of HR solutions for Small and Medium-sized Businesses (SMBs). The company operates a technology-enabled platform delivering a comprehensive suite of services including human capital expertise, employee benefits (health insurance, retirement plans), payroll and tax administration, risk mitigation, and compliance consulting.

Business Model & Evidence (as of 2026-06-20):

• Core Operations: The company processes payroll and administers benefits for its clients. As of the end of 2025, TriNet processed $70 billion in payroll and payroll taxes for its clients, serving approximately 323,200 Workforce Service Employees (WSEs) [E17].
• Service Evolution: In 2025, the company expanded its ASO (Administrative Services Only) offering to include "HR Plus," a SaaS solution combined with high-level service [E20]. ASO ARR has doubled year-over-year and is on track to become a meaningful contributor to professional service revenue growth [E6].
• Recent Performance & Challenges:
• Repricing Impact: In January 2026, the company implemented a repricing of health benefits services. This led to a 12% decrease in Average WSEs and Total WSEs in Q1 2026 compared to the prior year, primarily in Technology, Professional Services, and Main Street verticals [E11].
• Attrition & Recovery: Client attrition was higher than historical rates in the past twelve months due to these repricing increases [E13]. However, management reports a tangible improvement in Q2 2026, where attrition due to health pricing has declined by 30% [E2].
• Growth Drivers: Broker RFPs grew by nearly 12% year-over-year in Q1, with Q2 showing acceleration [E7]. In verticals with high AI adoption (e.g., Technology), client hiring has remained stable, suggesting AI is creating opportunities rather than displacing them [E8].
• Strategic Acquisitions: In April 2026, TriNet announced the purchase of Cocoon, a leading provider of leave management technology, to be integrated into its platform [E14].
• Financial Guidance (Management Expectations):
• Revenue: Management expects total revenues for 2026 to be in the range of $4.75 billion to $4.9 billion [E4].
• Margins & Earnings: Adjusted EBITDA margin is expected to remain between 7.5% and 8.7%. GAAP EPS is expected between $2.15 and $3.05, and Adjusted EPS between $3.70 and $4.70 [E5].
• Retention: Despite the January repricing, management expects overall 2026 retention to be better than the full year 2025 [E1].

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: TriNet fits the "Quality Compounder" archetype due to its dominant market position in the SMB HR space, its recurring revenue model (ASO/PEO), and its ability to navigate pricing cycles while maintaining margin discipline. The company is demonstrating a "margin inflector" capability through its repricing efforts, which have successfully aligned rates with insurance cost trends, leading to an improved Interest Coverage Ratio (ICR) [E12].

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro tailwind).
• Evidence Quality: High. Management has provided specific, quantified guidance for 2026 revenue, margins, and earnings, alongside clear metrics on the recovery from the repricing shock (30% drop in pricing-driven attrition) [E2, E4, E5].
• Rerating Potential: Moderate. If the company executes on the "solid full year sales growth" guidance [E3] and the ASO ARR doubling trend [E6], the market may re-rate the stock from a "repricing victim" to a "growth accelerator."

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: A significant miss on the 2026 revenue guidance ($4.75B–$4.9B) or a failure to maintain the projected adjusted EBITDA margin (7.5%–8.7%).
• Operational: A resurgence in client attrition driven by health pricing, contradicting the Q2 trend of a 30% decline in such attrition [E2].

What Would Strengthen the Case:

• Technical: A confirmed breakout above the resistance cap with volume, validating the "Forming" coil.
• Fundamental: Continued acceleration in Broker RFPs (Q2 accelerating off Q1's 12% growth) [E7] and further growth in ASO Users (currently 40,800 as of March 31, 2026) [E15].
• Strategic: Successful integration of the Cocoon acquisition leading to immediate cross-sell opportunities.

Gaps in Evidence:

• Specific Breakout Level: The exact resistance level (breakout price) is not defined in the provided evidence, as the setup is still forming.
• Post-Acquisition Synergy: While the Cocoon acquisition is announced, there is no evidence yet on the specific financial impact or integration timeline of this deal in the 2026 guidance.
• Long-term AI Impact: While management notes AI is not displacing hiring in tech verticals [E8], there is no quantitative data on how AI adoption specifically impacts TriNet's revenue per client or operational efficiency beyond this qualitative statement.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance for 2026 revenue ($4.75B-$4.9B) and earnings ($3.70-$4.70 adj EPS); tangible Q2 improvement in attrition due to health pricing (down 30%); ASO ARR doubling year-over-year. Key risks: Technical structure remains unconfirmed (forming coil, no breakout); potential for further WSE decline if repricing pressure persists; high volatility (4.6% ATR) increases execution risk. Sizing hint: Position size should be conservative given the "forming" status; scale in only upon confirmed breakout. Expected path: Management expects retention to improve and sales growth to be solid; if the breakout fires, the stock may re-rate based on the ASO growth narrative. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).